C4 THERAPEUTICS INC (CCCC)
Health Care · Targeted protein degradation / small-molecule therapeutics · NASDAQ
Clinical-stage biotech deploying its proprietary TORPEDO platform to develop first-in-class small-molecule targeted protein degraders for oncology, neuroinflammation, and neurodegeneration.
What C4 THERAPEUTICS INC does
C4 Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule targeted protein degraders (TPD) using its proprietary TORPEDO platform to degrade disease-causing proteins. The company's lead candidate, cemsidomide, is an orally bioavailable degrader of IKZF1 and IKZF3 in clinical development for multiple myeloma, while CFT8919 targets mutant EGFR in non-small cell lung cancer. C4 is also expanding its pipeline into inflammation, neuroinflammation, and neurodegeneration, including brain-penetrant degraders, and advancing partnerships with Roche and Merck KGaA on additional degrader programs.
Themes: Targeted protein degradation (TPD), Oncology (multiple myeloma, NSCLC), Inflammation and neuroinflammation, Neurodegeneration, CNS penetrant therapeutics
Fundamentals
- Price$4.00 as of 2026-08-21 close
- Market cap$492M as of 2026-08-21
- 1-year return+53.3% 2025-08-21 close $2.61 → 2026-08-21 close $4.00
- P/En/a negative earnings
- Net margin-297.8% as of 2026-08-24
- ROE-50.7% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)-12.4% as of 2026-08-24
- Revenue CAGR (3y)+5.0% SEC XBRL
- Beta3.07 as of 2026-08-24
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How CCCC compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How C4 THERAPEUTICS INC looks technically
C4 THERAPEUTICS INC (CCCC) is trading 35.7% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 112 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 5 trading days ago. It is 22.6% below its highest point of the past year. Trading volume is unusually light — only about 43% of its 30-day average.
Trend
7
| Distance from the 200-day | it is trading 35.7% above its 200-day average, the long-term trend line — a longer-term uptrend | +35.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $3.93 | $3.93 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $2.95 | $2.95 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 18 calendar days ago — the swings before that are what the structure reading is measured on | 18 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 112 trading days ago — a "golden cross", a bullish long-term signal | 112 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend) | 18.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 54, neither overbought (above 70) nor oversold (below 30) | 53.6 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($3.47 to $4.38) — its "stochastic" reading is 59 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 58.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 12 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $5.17 | $5.17 |
|---|---|---|
| From the 52-week high | it is 22.6% below its 52-week high (its highest price of the past year) | -22.6% |
| Above the 52-week low | it is 136.7% above its 52-week low (its lowest price of the past year) | +136.7% |
| Below the 52-week high | it is 22.6% below its highest point of the past year | 22.6% |
| Since a 20-day breakout | it made a new 20-day high about 5 trading days ago | 5 sessions |
| Since a 55-day breakout | it made a new 55-day high about 38 trading days ago | 38 sessions |
| All-time high | its highest closing price on record is $51.21 (set on 2021-09-23) | $51.21 |
| Given back of the 52-week move | over the past year its closes ranged ($1.71 to $4.67), and it has given back roughly a quarter of its rise from last year’s low — 23% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $2.75 to $2.84. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 22.6% |
| From the all-time high | it is 92.2% below its all-time high | -92.2% |
| Nearest price level | it is trading 1.3% above a support level at $3.95 — a price it turned at twice since 2026-05-13, most recently on 2026-07-22. Since 2024-08-21 it has 9 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.3% |
| All-time low | its lowest closing price on record is $1.06 (set on 2023-12-06) | $1.06 |
| Above the all-time low | it is 277.4% above its all-time low | +277.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 43rd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2551 between its high and its low — about 6.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2551 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.28 and $4.35 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.28 – $3.81 – $4.35 |
| Typical daily range (% of price) | its price moves about 6.4% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.4% |
| Stretch from the 200-day average | it is trading 4.1 daily ranges above its 200-day average price (35.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 43% of its 30-day average | 0.43× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a doji | 8 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 8 sessions ago |
|---|---|---|
| Since a bearish engulfing | 9 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 9 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.0% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.0% |
|---|---|---|
| Open gap | it gapped 6.1% above the previous close 8 sessions ago and has not traded back through the level it left behind at 3.62 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +6.1% |
| Gap filled | a 2.1% gap up opened on 2026-08-12 has been "filled" 7 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 7 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -4.99% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 2.1 percentage points (the stock gained 4.4% while the market gained 2.3%) | +2.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 10.5 percentage points (the stock gained 13.6% while the market gained 3.1%) | +10.5% |
| vs market, 6 months | over the past 6 months this stock beat the market by 74.1 percentage points (the stock gained 85.2% while the market gained 11.1%) | +74.1% |
| vs market, 12 months | over the past 12 months this stock beat the market by 32.8 percentage points (the stock gained 53.3% while the market gained 20.5%) | +32.8% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is moderate, spanning 7.7% of the share price. | 0.0% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 19% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $3.36 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +19.2% |
|---|
Price levels it has turned at before
CCCC last closed at $4.00 on 2026-08-21. Since 2024-08-21 it has turned at 9 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $3.95 | Support | 1.3% below the last close | turned there twice · 2026-05-13 to 2026-07-22 |
| $3.82 | Support | 4.6% below the last close | turned there four times · 2024-11-20 to 2026-03-09 |
| $3.63 | Support | 9.3% below the last close | turned there twice · 2024-12-18 to 2025-09-15 |
| $4.58 | Resistance | 14.5% above the last close | turned there twice · 2024-09-09 to 2026-06-01 |
| $5.13 | Resistance | 28.4% above the last close | turned there twice · 2024-12-09 to 2026-06-30 |
| $7.18 | Resistance | 79.5% above the last close | turned there twice · 2024-09-13 to 2024-10-16 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · trendless / choppy (low ADX) · beating the market · Most volatile (6%+ typical daily range) · Trading inside the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.14 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$13.33 range $7.00 – $30.00; median $11.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CCCC
- Consensus EPS estimate-$0.23 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical-stage company with no approved products or product revenue; all revenue derived from collaboration agreements, subject to discontinuation or milestone achievement.","Development timelines and regulatory approval uncertain; potential failures in Phase 2 MOMENTUM trial or Phase 1b trials of cemsidomide could delay or prevent commercialization.","Dependence on partnerships with Pfizer, Roche, and other collaborators; loss or termination of these agreements could reduce development capacity and financial resources."]
What changed in the latest 10-Q
AI-assisted comparison of CCCC's 10-Q filed 2026-05-12 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- April 2026: Entered into 2026 Roche Agreement with Roche to advance research in emerging DAC modality (newer filing, 2026-05-12)
- March 2026: First patient dosed in Phase 1b trial evaluating cemsidomide, dexamethasone, and elranatamab combination (newer filing, 2026-05-12)
- February 2026: First patient dosed in Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone (newer filing, 2026-05-12)
- Plan to initiate Phase 1b trial in first half 2027 evaluating cemsidomide in additional combinations with approved multiple myeloma therapies (newer filing, 2026-05-12)
- Removed:
- Reference to Form 10-K for year ended December 31, 2024, filed February 27, 2025 (older filing, 2025-11-06)
- Cemsidomide clinical development in non-Hodgkin lymphoma (NHL) indication (older filing, 2025-11-06)
- December 2024 Phase 1 data in NHL showing well-tolerated profile and anti-lymphoma activity (older filing, 2025-11-06)
- Reference to PTCL (peripheral T-cell lymphoma) results (older filing, 2025-11-06)
- Statement that company is prioritizing cemsidomide development in MM (older filing, 2025-11-06)
- Expected initiation of Phase 1b trial with elranatamab and registrational Phase 2 trial in 2026 (older filing, 2025-11-06)
- CFT1946 product candidate description and decision not to advance beyond Phase 1 (older filing, 2025-11-06)
- Reference to BRAF V600 mutant melanoma, CRC, and brain metastases (older filing, 2025-11-06)
- September 2024 CFT1946 Phase 1/2 monotherapy data (older filing, 2025-11-06)
- Merck collaboration mentioned in collaboration agreements list (older filing, 2025-11-06)
- September 2025 Pfizer clinical trial collaboration and supply agreement details (older filing, 2025-11-06)
- October 2025 underwriting agreement and warrant offering details with net proceeds of $117.0 million (older filing, 2025-11-06)
- Reworded:
- Form 10-K reference updated from year ended December 31, 2024 (older) to year ended December 31, 2025, filed February 26, 2026 (newer)
- Business overview section reorganized: removed initial strategy sentence about selecting targets with best-in-class or first-in-class potential and added it after TORPEDO platform description in newer filing
- Cemsidomide development focus narrowed: older filing mentions both MM and NHL development; newer filing focuses primarily on MM with no mention of NHL or PTCL
- Cemsidomide development timeline changed from expected initiation in 2026 (older) to already initiated in February-March 2026 (newer)
- CFT8919 description slightly expanded in newer filing with note that Betta Pharma trial will inform ex-China development strategy (removed from newer)
- Pipeline diversification description simplified in newer filing, removing specific mention of areas beyond oncology detail present in older filing
- Notes:
- The older filing (2025-11-06) covered nine-month period ending September 30, 2025; the newer filing (2026-05-12) covers three-month period ending March 31, 2026, resulting in expected temporal updates to recent developments and clinical trial status
- Some removals reflect completed milestones (warrant offering, Pfizer agreement) that would naturally not be repeated as recent developments in a later quarter
Risk Factors
- Added:
- Reference updated from 'Annual Report on Form 10-K for the year ended December 31, 2024' to 'Annual Report on Form 10-K for the year ended December 31, 2025' (filed 2026-05-12)
- Removed:
- Asterisk designation ('*') removed from the risk factor heading 'We will need substantial additional funding to pursue our business objectives and continue our operations' (filed 2026-05-12)
- Reference to 'first-in-human Phase 1/2 clinical trials' removed and replaced with generic reference to 'clinical trials' (filed 2026-05-12)
- Reworded:
- Net loss figures changed from '$84.5 million and $70.7 million for nine months ended September 30, 2025 and 2024' to '$25.1 million and $26.3 million for the three months ended March 31, 2026 and 2025' (filed 2026-05-12)
- Accumulated deficit changed from '$718.2 million as of September 30, 2025' to '$763.8 million as of March 31, 2026' (filed 2026-05-12)
- Cash, cash equivalents, and marketable securities changed from 'approximately $199.8 million as of September 30, 2025' to 'approximately $268.3 million as of March 31, 2026' (filed 2026-05-12)
- Reference to 'shares' capitalized to 'Shares' and 'pre-funded warrants' capitalized to 'Pre-Funded Warrants' (filed 2026-05-12)
- Phrase 'approved product candidates' changed to 'approved products' in one instance (filed 2026-05-12)
- Notes:
- The newer filing text appears truncated at the end, so the complete comparison of the funding section and any subsequent risk factors cannot be fully assessed
- Removal of asterisk notation may indicate that this risk factor is no longer considered newly added or materially updated as of the newer filing date
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for CCCC — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding CCCC as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 7,754,297
- Reported value $20,393,798
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 5 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
CCCC had 30,427,514 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
CCCC had 24.7% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 11.12 days to cover at the same settlement.
- Reported short interest (shares) 30,427,514
- Short interest (% of shares outstanding) 24.7%
- Prior settlement (shares) 23,815,010
- Reported change 27.77%
- Days to cover (reported) 11.12
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Kura Oncology (KURA)
- Cullgen
- Nurix Therapeutics (NRIX)
- Protac Therapeutics
- Editas Medicine (NASDAQ: EDIT)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CCCC vs…
Frequently asked questions
What does C4 THERAPEUTICS INC (CCCC) do?
C4 Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule targeted protein degraders (TPD) using its proprietary TORPEDO platform to degrade disease-causing proteins. The company's lead candidate, cemsidomide, is an orally bioavailable degrader of IKZF1 and IKZF3 in clinical development for multiple myeloma, while CFT8919 targets mutant EGFR in non-small cell lung cancer.
What sector is C4 THERAPEUTICS INC (CCCC) in?
C4 THERAPEUTICS INC (CCCC) is classified in the Health Care sector. Its industry is Targeted protein degradation / small-molecule therapeutics. It trades on NASDAQ.
Who are C4 THERAPEUTICS INC's (CCCC) competitors?
Notable peers of C4 THERAPEUTICS INC (CCCC) include Kura Oncology, Cullgen, Nurix Therapeutics, Protac Therapeutics and Editas Medicine (NASDAQ: EDIT). This peer set is informational only — not financial advice.
Is C4 THERAPEUTICS INC (CCCC) overbought or oversold right now?
C4 THERAPEUTICS INC (CCCC) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 54, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CCCC come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.